Innovative therapeutics

Investors

SEC Filings

NASDAQBMRN
FormDescriptionDateFormat
4Statement of changes in beneficial ownership of securitiesSep 30, 2019View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesSep 18, 2019View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesAug 8, 2019View HTMLDownload DOCDownload PDFDownload XLS
10-QQuarterly report which provides a continuing view of a company's financial positionAug 2, 2019View HTMLDownload DOCDownload PDFDownload XLSView XBRLDownload XBRL
8-KReport of unscheduled material events or corporate eventAug 1, 2019View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJul 12, 2019View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJul 11, 2019View HTMLDownload DOCDownload PDFDownload XLS
3Initial filing by director officer or owner of more than ten percent.Jul 11, 2019View HTMLDownload DOCDownload PDFDownload XLS
8-KReport of unscheduled material events or corporate eventJul 10, 2019View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJun 19, 2019View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJun 10, 2019View HTMLDownload DOCDownload PDFDownload XLS
8-KReport of unscheduled material events or corporate eventJun 7, 2019View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJun 7, 2019View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJun 7, 2019View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJun 7, 2019View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJun 7, 2019View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJun 7, 2019View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJun 6, 2019View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJun 6, 2019View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJun 6, 2019View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJun 6, 2019View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJun 6, 2019View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJun 6, 2019View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJun 6, 2019View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJun 6, 2019View HTMLDownload DOCDownload PDFDownload XLS
1-25      26-50      51-75      76-100      101-109

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information